WAT

Waters Corporation (WAT) - Q3 2007 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 29, 2007, and the nine-month period ended on the same date. Waters Corporation designs, manufactures, and services analytical instrument systems, including high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC), mass spectrometry (MS), and thermal analysis instruments. The company operates through two primary divisions: the Waters Division and the TA Division.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 17% in Q3 and 16% for the nine-month period compared to the prior year. Growth was driven by new product introductions (ACQUITY UPLC, Q-Tof Premier, Synapt HDMS), increased spending by pharmaceutical and government customers, and benefits from 2006 acquisitions.
• Margin Compression: Gross margin decreased to 56.4% in Q3 from 57.8% in Q3 2006. This was attributed to a higher mix of instrument sales with higher manufacturing costs, unfavorable foreign currency impacts on UK-manufactured MS products, and a $2.6 million charge related to a pension plan contribution.
• Unusual Charges: The company recorded a $12.6 million charge in Q3 2007 related to a contribution into the Waters Employee Investment Plan to assist employees transitioning to a frozen pension plan. This charge was allocated across cost of sales, selling/administrative, and R&D expenses.
• Acquisitions: In August 2007, the company acquired Calorimetry Sciences Corporation (CSC) for $7.1 million. In June 2007, it made a $3.5 million equity investment in Thar Instruments, Inc.
• Debt Restructuring: In January 2007, the company entered a new credit agreement with a $500 million term loan and $600 million in revolving facilities, replacing prior agreements. Total borrowings under the new agreement were $895.0 million as of September 29, 2007.

Guidance, Outlook, and Risks

• Outlook: Management anticipates gross profit percentages to improve in the fourth quarter of 2007 as volume efficiencies are achieved on new products. Selling and administrative expenses are expected to increase at a lower rate in Q4.
• Pension Changes: The Board approved freezing pay credit accruals under U.S. pension plans effective December 31, 2007, and increasing the 401(k) employer match by 3% effective January 1, 2008.
• Share Repurchases: The company repurchased $180.7 million of stock in the first nine months of 2007. The 2005 repurchase program ($500M) was completed, and $353.8 million remains authorized under the 2007 program.
• Risks: Key risks include reliance on pharmaceutical industry spending (approx. 53% of sales), foreign currency fluctuations (68% of sales outside the U.S.), supply chain disruptions, and intellectual property litigation.

Investor Verification Checklist

• Impact of Pension Charge: Verify the non-recurring nature of the $12.6 million charge and its specific impact on Q3 operating margins versus underlying operational performance.
• Foreign Currency Sensitivity: Assess the exposure to the Euro and British Pound, given that 68% of sales are international and currency translation impacted both revenue and costs.
• Acquisition Integration: Monitor the integration and revenue contribution of the recent CSC acquisition and the ongoing impact of 2006 acquisitions (ERA, VICAM, Thermometric).
• Debt Covenants: Confirm compliance with the new credit agreement covenants, specifically the 3.50:1 interest coverage ratio and 3.25:1 leverage ratio.
• Inventory Levels: Review the increase in inventory ($191.1M vs $168.4M prior year-end) to ensure it aligns with sales growth and does not indicate obsolescence risks.